Review



rabbit anti-mouse il-17rd antibody  (Absolute Biotech Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Absolute Biotech Inc rabbit anti-mouse il-17rd antibody
    Primer for real-time PCR.
    Rabbit Anti Mouse Il 17rd Antibody, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti-mouse il-17rd antibody/product/Absolute Biotech Inc
    Average 90 stars, based on 1 article reviews
    rabbit anti-mouse il-17rd antibody - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells"

    Article Title: The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0169702

    Primer for real-time PCR.
    Figure Legend Snippet: Primer for real-time PCR.

    Techniques Used: Sequencing

    (A) Results of luciferase assay. Reporter plasmid and mouse pmG/mIl17rd were transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of the negative control vector. **p < 0.01. (B) Expression of miR-223-3p in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (C) Expression of Il17rd mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (D) Results of western blot analysis. (E) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. **p < 0.01. (F) Expression of Il6 mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. All results are presented as the means ± S.E. for each group (n = 3).
    Figure Legend Snippet: (A) Results of luciferase assay. Reporter plasmid and mouse pmG/mIl17rd were transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of the negative control vector. **p < 0.01. (B) Expression of miR-223-3p in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (C) Expression of Il17rd mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (D) Results of western blot analysis. (E) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. **p < 0.01. (F) Expression of Il6 mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. All results are presented as the means ± S.E. for each group (n = 3).

    Techniques Used: Luciferase, Plasmid Preparation, Transfection, Over Expression, Negative Control, Activity Assay, Expressing, Western Blot

    (A) Schematic diagram of the luciferase reporter plasmids including IL-17RD3’UTR wild type (WT) or deleted (del) miR-223-3p binding sequences in the 3’UTR in which six nucleotide forming the seed region of miR-223-3p were deleted. (B) Results of luciferase assay. Either pmG/ hIl17rd WT or pmG /hIl17rd del was transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of cells with the negative control vector. *p<0.05 as compared with the pBA/NC group, #p<0.05 as compared with the pmG/ hIL17rd WT group. (C) Results of miR-223-3p expression in MH7A cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (D) Results of Il17rd mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection of the negative control vector; ***p < 0.001. (E) Results of western blot analysis. (F) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. *p < 0.05. (G) Results of Il6 mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (H) Effect of miR-223-3p inhibitor on Il17rd mRNA expression. Results were expressed as the relative fold change with the negative control (NC). *p < 0.05. All results are presented as the means ± S.E. for each group (n = 3).
    Figure Legend Snippet: (A) Schematic diagram of the luciferase reporter plasmids including IL-17RD3’UTR wild type (WT) or deleted (del) miR-223-3p binding sequences in the 3’UTR in which six nucleotide forming the seed region of miR-223-3p were deleted. (B) Results of luciferase assay. Either pmG/ hIl17rd WT or pmG /hIl17rd del was transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of cells with the negative control vector. *p<0.05 as compared with the pBA/NC group, #p<0.05 as compared with the pmG/ hIL17rd WT group. (C) Results of miR-223-3p expression in MH7A cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (D) Results of Il17rd mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection of the negative control vector; ***p < 0.001. (E) Results of western blot analysis. (F) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. *p < 0.05. (G) Results of Il6 mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (H) Effect of miR-223-3p inhibitor on Il17rd mRNA expression. Results were expressed as the relative fold change with the negative control (NC). *p < 0.05. All results are presented as the means ± S.E. for each group (n = 3).

    Techniques Used: Luciferase, Binding Assay, Transfection, Over Expression, Plasmid Preparation, Negative Control, Activity Assay, Expressing, Western Blot

    The expression of IL-17RD in synovial cells by SKG mice with mild arthritis (arthritis score:0.5) (A) was higher than that by SKG mice with severe arthritis (arthritis score:2.5) (B). The expression of IL-6 in synovial tissues from SKG mice with mild arthritis (C) was lower than that from SKG mice with severe arthritis (D).The expression of IL-17RD in synovial tissues from RA patients with mild arthritis (stage 2) (E) was higher than that from RA patients with severe arthritis (stage 4) (F). Original magnification, ×200.
    Figure Legend Snippet: The expression of IL-17RD in synovial cells by SKG mice with mild arthritis (arthritis score:0.5) (A) was higher than that by SKG mice with severe arthritis (arthritis score:2.5) (B). The expression of IL-6 in synovial tissues from SKG mice with mild arthritis (C) was lower than that from SKG mice with severe arthritis (D).The expression of IL-17RD in synovial tissues from RA patients with mild arthritis (stage 2) (E) was higher than that from RA patients with severe arthritis (stage 4) (F). Original magnification, ×200.

    Techniques Used: Expressing



    Similar Products

    rabbit anti-mouse il-17rd antibody  (Absolute Biotech Inc)
    90
    Absolute Biotech Inc rabbit anti-mouse il-17rd antibody
    Primer for real-time PCR.
    Rabbit Anti Mouse Il 17rd Antibody, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti-mouse il-17rd antibody/product/Absolute Biotech Inc
    Average 90 stars, based on 1 article reviews
    rabbit anti-mouse il-17rd antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Primer for real-time PCR.

    Journal: PLoS ONE

    Article Title: The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells

    doi: 10.1371/journal.pone.0169702

    Figure Lengend Snippet: Primer for real-time PCR.

    Article Snippet: After blocking nonspecific binding with 10% normal rabbit serum in PBS, the sections were incubated with rabbit anti-mouse IL-6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse TNF-α antibody (Santa Cruz), rabbit anti-mouse IL-17 antibody (Santa Cruz), or rabbit anti-mouse IL-17RD antibody (LifeSpan Biosciences, Inc. Seattle, WA, USA) at appropriate dilutions for 1 h at room temperature, washed, incubated with biotinylated goat anti-rabbit IgG, washed again and incubated with avidin-biotinylated horseradish peroxidase complex (ABC) and 3,3'-diaminobenzidine tetrahydrochloride (DAB) (VECTASTAIN Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA) and counterstained with Mayer's hematoxylin.

    Techniques: Sequencing

    (A) Results of luciferase assay. Reporter plasmid and mouse pmG/mIl17rd were transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of the negative control vector. **p < 0.01. (B) Expression of miR-223-3p in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (C) Expression of Il17rd mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (D) Results of western blot analysis. (E) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. **p < 0.01. (F) Expression of Il6 mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. All results are presented as the means ± S.E. for each group (n = 3).

    Journal: PLoS ONE

    Article Title: The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells

    doi: 10.1371/journal.pone.0169702

    Figure Lengend Snippet: (A) Results of luciferase assay. Reporter plasmid and mouse pmG/mIl17rd were transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of the negative control vector. **p < 0.01. (B) Expression of miR-223-3p in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (C) Expression of Il17rd mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (D) Results of western blot analysis. (E) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. **p < 0.01. (F) Expression of Il6 mRNA in miR-223-3p overexpression NIH3T3 cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. All results are presented as the means ± S.E. for each group (n = 3).

    Article Snippet: After blocking nonspecific binding with 10% normal rabbit serum in PBS, the sections were incubated with rabbit anti-mouse IL-6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse TNF-α antibody (Santa Cruz), rabbit anti-mouse IL-17 antibody (Santa Cruz), or rabbit anti-mouse IL-17RD antibody (LifeSpan Biosciences, Inc. Seattle, WA, USA) at appropriate dilutions for 1 h at room temperature, washed, incubated with biotinylated goat anti-rabbit IgG, washed again and incubated with avidin-biotinylated horseradish peroxidase complex (ABC) and 3,3'-diaminobenzidine tetrahydrochloride (DAB) (VECTASTAIN Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA) and counterstained with Mayer's hematoxylin.

    Techniques: Luciferase, Plasmid Preparation, Transfection, Over Expression, Negative Control, Activity Assay, Expressing, Western Blot

    (A) Schematic diagram of the luciferase reporter plasmids including IL-17RD3’UTR wild type (WT) or deleted (del) miR-223-3p binding sequences in the 3’UTR in which six nucleotide forming the seed region of miR-223-3p were deleted. (B) Results of luciferase assay. Either pmG/ hIl17rd WT or pmG /hIl17rd del was transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of cells with the negative control vector. *p<0.05 as compared with the pBA/NC group, #p<0.05 as compared with the pmG/ hIL17rd WT group. (C) Results of miR-223-3p expression in MH7A cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (D) Results of Il17rd mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection of the negative control vector; ***p < 0.001. (E) Results of western blot analysis. (F) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. *p < 0.05. (G) Results of Il6 mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (H) Effect of miR-223-3p inhibitor on Il17rd mRNA expression. Results were expressed as the relative fold change with the negative control (NC). *p < 0.05. All results are presented as the means ± S.E. for each group (n = 3).

    Journal: PLoS ONE

    Article Title: The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells

    doi: 10.1371/journal.pone.0169702

    Figure Lengend Snippet: (A) Schematic diagram of the luciferase reporter plasmids including IL-17RD3’UTR wild type (WT) or deleted (del) miR-223-3p binding sequences in the 3’UTR in which six nucleotide forming the seed region of miR-223-3p were deleted. (B) Results of luciferase assay. Either pmG/ hIl17rd WT or pmG /hIl17rd del was transfected into HeLa cells with either miR-223-3p overexpression vector (pBA/miR-223-3p) or negative control vector (pBA/NC). Results were expressed as the relative luciferase activity following transfection of cells with the negative control vector. *p<0.05 as compared with the pBA/NC group, #p<0.05 as compared with the pmG/ hIL17rd WT group. (C) Results of miR-223-3p expression in MH7A cells. Results were expressed as the relative fold change following transfection of cells with the negative control vector. ***p < 0.001. (D) Results of Il17rd mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection of the negative control vector; ***p < 0.001. (E) Results of western blot analysis. (F) Relative expression of IL-17RD protein. IL17RD expression was normalized to that of β-actin in the same sample, and results were expressed as a percentage of the expression following transfection with the negative control vector. *p < 0.05. (G) Results of Il6 mRNA expression in MH7A cells. Results were expressed as the relative fold change following transfection with the negative control vector. ***p < 0.001. (H) Effect of miR-223-3p inhibitor on Il17rd mRNA expression. Results were expressed as the relative fold change with the negative control (NC). *p < 0.05. All results are presented as the means ± S.E. for each group (n = 3).

    Article Snippet: After blocking nonspecific binding with 10% normal rabbit serum in PBS, the sections were incubated with rabbit anti-mouse IL-6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse TNF-α antibody (Santa Cruz), rabbit anti-mouse IL-17 antibody (Santa Cruz), or rabbit anti-mouse IL-17RD antibody (LifeSpan Biosciences, Inc. Seattle, WA, USA) at appropriate dilutions for 1 h at room temperature, washed, incubated with biotinylated goat anti-rabbit IgG, washed again and incubated with avidin-biotinylated horseradish peroxidase complex (ABC) and 3,3'-diaminobenzidine tetrahydrochloride (DAB) (VECTASTAIN Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA) and counterstained with Mayer's hematoxylin.

    Techniques: Luciferase, Binding Assay, Transfection, Over Expression, Plasmid Preparation, Negative Control, Activity Assay, Expressing, Western Blot

    The expression of IL-17RD in synovial cells by SKG mice with mild arthritis (arthritis score:0.5) (A) was higher than that by SKG mice with severe arthritis (arthritis score:2.5) (B). The expression of IL-6 in synovial tissues from SKG mice with mild arthritis (C) was lower than that from SKG mice with severe arthritis (D).The expression of IL-17RD in synovial tissues from RA patients with mild arthritis (stage 2) (E) was higher than that from RA patients with severe arthritis (stage 4) (F). Original magnification, ×200.

    Journal: PLoS ONE

    Article Title: The Impact of MicroRNA-223-3p on IL-17 Receptor D Expression in Synovial Cells

    doi: 10.1371/journal.pone.0169702

    Figure Lengend Snippet: The expression of IL-17RD in synovial cells by SKG mice with mild arthritis (arthritis score:0.5) (A) was higher than that by SKG mice with severe arthritis (arthritis score:2.5) (B). The expression of IL-6 in synovial tissues from SKG mice with mild arthritis (C) was lower than that from SKG mice with severe arthritis (D).The expression of IL-17RD in synovial tissues from RA patients with mild arthritis (stage 2) (E) was higher than that from RA patients with severe arthritis (stage 4) (F). Original magnification, ×200.

    Article Snippet: After blocking nonspecific binding with 10% normal rabbit serum in PBS, the sections were incubated with rabbit anti-mouse IL-6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse TNF-α antibody (Santa Cruz), rabbit anti-mouse IL-17 antibody (Santa Cruz), or rabbit anti-mouse IL-17RD antibody (LifeSpan Biosciences, Inc. Seattle, WA, USA) at appropriate dilutions for 1 h at room temperature, washed, incubated with biotinylated goat anti-rabbit IgG, washed again and incubated with avidin-biotinylated horseradish peroxidase complex (ABC) and 3,3'-diaminobenzidine tetrahydrochloride (DAB) (VECTASTAIN Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA) and counterstained with Mayer's hematoxylin.

    Techniques: Expressing